India To Use Ranbaxy Bid For Parity In Japanese Trade Talks
This article was originally published in PharmAsia News
Executive Summary
India's government plans to take advantage of Daiichi Sankyo's bid to buy Ranbaxy Laboratories in its current negotiations with Japan for a bilateral trade and investment agreement. Indian negotiators plan to use the case to press Japan to make its highly protected drug makers susceptible to similar buyout bids by Indian companies. The two countries are negotiating a comprehensive economic partnership agreement, with the next meeting set for next month in Tokyo. An Indian commerce official said Japan has regulations that make it harder for foreign companies to buy into Japanese firms. (Click here for more
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.